OpenAI Records, YouTube Addiction Claims, Pfizer, and J&J: Litigation Tracker — Week of June 29
This week's tracker covers six litigation signals across AI, tech, and pharma: a new publisher copyright suit against OpenAI and Microsoft, a court order allowing a warrant for ChatGPT records, YouTube's social-media addiction settlement, New York's hate-speech reporting law, Pfizer's generic-drug antitrust dismissal, and the FTC's Stelara amicus against J&J.
The window for this issue is June 23-29, 2026. Six matters cleared the materiality bar this week: two AI evidence and copyright disputes, two social-platform cases testing youth-safety and speech-regulation boundaries, and two pharma antitrust developments. No separate qualifying pharma patent or Hatch-Waxman filing appeared in the checked source set during this window; the pharma signal this week is antitrust-heavy.
At-a-glance docket
| Sector | Matter | Forum | This week's event | Why it matters next |
|---|---|---|---|---|
| AI | United States v. Richard Kim | S.D.N.Y., No. 1:25-cr-00359-LGS | Judge Lorna Schofield lifted a temporary block on a warrant seeking records from OpenAI in a securities-fraud prosecution. 1 | Courts are starting to define when AI-chat records are searchable, and when privilege objections must be raised after production rather than before it. |
| AI | Richner Communications et al. v. Microsoft/OpenAI | S.D.N.Y., No. 1:26-cv-05320 | A group led by Richner Communications filed a 55-page complaint accusing OpenAI and Microsoft of scraping content from nearly 400 local and regional newspapers. 2 | The case adds a local-news plaintiff bloc to the AI-training copyright docket and makes copyright-management-information stripping a central theory. |
| Tech | R.K.C. v. YouTube / Meta / Snap / TikTok | California state court | YouTube confidentially settled with a 15-year-old Florida plaintiff ahead of the second California trial over youth social-media addiction claims. 3 | Meta, Snap and TikTok remain set for a July 27 trial, so one defendant's exit does not end the bellwether pressure. |
| Tech | Volokh et al. v. James | New York Court of Appeals / 2nd Circuit certified question | New York's top court said the state's Hateful Conduct Law likely survives First Amendment scrutiny because it requires reporting channels, not adoption of the state's speech view. 4 | The 2nd Circuit still decides the federal constitutional challenge, but the state-law interpretation narrows the platforms' compelled-speech argument. |
| Pharma | States v. generic drugmakers, including Pfizer/Greenstone | D. Conn. | Chief Judge Michael Shea dismissed Pfizer from a multistate generic-drug price-fixing suit after finding insufficient evidence that Pfizer directly conspired or was liable through Greenstone. 5 | The ruling tests how far parent-company liability can reach in sprawling generic-drug antitrust cases. |
| Pharma | CareFirst of Maryland et al. v. Johnson & Johnson | 4th U.S. Circuit Court of Appeals | The FTC filed an amicus brief arguing that monopolization under Section 2 does not require proof of specific intent to exclude rivals. 6 | A Fourth Circuit reversal could make it easier for payors to challenge biologic life-cycle strategies built around acquisitions and patent enforcement. |
AI and copyright: local news publishers file a new OpenAI/Microsoft suit
Parties
Richner Communications and a coalition of local and regional newspaper publishers sued Microsoft, OAI Corporation, OpenAI Foundation and related OpenAI entities in the Southern District of New York. Courthouse News reports that the plaintiffs own or operate nearly 400 newspapers, and that the complaint is led by Long Island-based Richner Communications. 2
Claims
The publishers allege three counts of copyright infringement. They claim OpenAI and Microsoft crawled newspaper websites, copied articles onto their servers, stripped copyright-management information such as author credits and publication names, and used the material to train ChatGPT and Microsoft Copilot. 2
Current stage
The complaint was filed Wednesday evening in Manhattan federal court; Courthouse News published its report on June 25. Representatives for OpenAI and Microsoft did not immediately respond to that outlet's requests for comment. 2
Recent developments
The complaint frames local journalism as both the source material and the threatened market. The plaintiffs say the alleged copying and stripping of attribution helped sever links between the works and their owners, then allowed AI products to reproduce or approximate the journalism in user responses. 2
Business impact
For AI developers, the case is another suit against the training-data supply chain, but the plaintiff profile differs from book authors and national publishers: local papers can argue that AI substitution hits a market already under financial pressure. For publishers, statutory damages and discovery into ingestion pipelines are the leverage points.
Precedent value
The case may sharpen two issues in the AI copyright docket: whether local-news archives receive different market-harm treatment from other text corpora, and whether removal of copyright-management information can survive as a distinct liability theory alongside direct copyright claims.
Next milestone
A public response deadline for OpenAI and Microsoft was not reported in the sources reviewed. The next public milestone is likely the defendants' first responsive pleading or a consolidation/coordination move with related AI copyright litigation in the Southern District of New York.
AI evidence: OpenAI records warrant allowed in securities-fraud case
Parties
The matter is United States v. Richard Kim in the Southern District of New York. Kim is charged with securities fraud and wire fraud over his crypto venture Zero Edge; he has pleaded not guilty. OpenAI is not a party. 1
Claims
The litigation event is not a civil claim against OpenAI. Prosecutors sought records of Kim's communications with AI chatbots, arguing that his OpenAI account and a rival AI-platform account likely contain evidence about the alleged investor-fraud scheme. Kim argued the warrant was overbroad and could expose defense-strategy material. 1
Current stage
Judge Lorna Schofield denied Kim's bid to block the warrant and lifted a temporary block. Reuters reported that the ruling does not prevent Kim from later arguing that prosecutors should be barred from using specific evidence obtained from OpenAI. 1
Recent developments
The government argued that AI-platform communications are not privileged because chatbots are not lawyers, users cannot reasonably expect confidentiality with them, and the tools do not provide legal advice. Prosecutors also told the court they were prepared to respect properly justified privilege assertions after defense counsel reviewed produced data. 1
Business impact
AI platform operators should expect more law-enforcement and civil-discovery fights over retained prompt and chat histories. Enterprise customers will also read the order as another reason to pin down retention, access-control and privilege-review processes before employees use general-purpose AI tools for sensitive matters.
Precedent value
The order follows a February ruling by Judge Jed Rakoff that prosecutors could obtain a defendant's Claude communications and that those exchanges were not protected by attorney-client privilege. 1 Together, the early rulings point toward a narrow view of privilege for AI-chat interactions unless a licensed lawyer and a protected legal-advice channel are clearly involved.
Next milestone
No hearing date or production deadline was publicly reported. Watch for any privilege log dispute or motion to suppress after the government receives and reviews the AI-platform records.
Tech product liability: YouTube exits one social-media addiction bellwether
Parties
The plaintiff, identified as R.K.C., is a 15-year-old Florida boy. His California state-court case named YouTube, Meta's Instagram, Snap's Snapchat and ByteDance's TikTok. 3
Claims
R.K.C. alleges that he began using social media around age eight, became addicted, lost sleep, and suffered depression and anxiety. The broader theory is that social-media platforms were deliberately designed to be addictive and harmful to young users. 3
Current stage
YouTube settled confidentially before the second California state-court trial. The remaining defendants, Meta, Snap and TikTok, are still scheduled for trial on July 27. 3
Recent developments
The settlement follows a March trial in which a jury found Meta and Google negligent and awarded $4.2 million against Meta and $1.8 million against Google. Reuters also reported that more than 3,300 addiction-claim suits are pending in California state court, while another 2,600 cases from individuals, school districts, municipalities and states are pending in California federal court. 3
Business impact
The settlement reduces YouTube's immediate trial risk but leaves the platform exposed in the wider state, municipal and individual docket. For Meta, Snap and TikTok, the July 27 trial becomes the next live test of whether plaintiffs can repeat or expand the March negligence win.
Precedent value
The important legal question is whether platform-design choices can be treated as negligent product design rather than protected editorial or speech decisions. A second plaintiff-side verdict would strengthen settlement pressure across the consolidated docket; a defense win would give platforms a trial record to use against later bellwethers.
Next milestone
The next public milestone is the July 27 California state-court trial against Meta, Snap and TikTok, unless those defendants also settle before trial.
Tech speech regulation: New York's hate-speech reporting law survives state-court interpretation
Parties
The challengers are blogger and UCLA professor Eugene Volokh plus the platforms Rumble and Locals. New York Attorney General Letitia James is defending the law. 4
Claims
The challengers argue that New York's Hateful Conduct Law violates the First Amendment. The law requires social-media platforms to provide a mechanism for users to report hateful conduct and to publicize policies on how they respond to those reports. 4
Current stage
In a 4-3 decision, the New York Court of Appeals answered certified questions from the 2nd Circuit and said the law likely does not violate free-speech protections because it requires reporting infrastructure, not platform endorsement of the state's definition of hateful conduct. 4
Recent developments
Judge Anthony Cannataro wrote for the majority that the law was not meant to regulate moderation decisions or compel networks to endorse the state's view. Three judges dissented, saying the law still requires companies to reference the state's definition of hateful conduct. 4
Business impact
If the 2nd Circuit accepts the state court's narrower reading, platforms may need to maintain hate-speech reporting channels and publish response policies without changing moderation outcomes. That is a lower operational burden than direct takedown mandates, but it still creates compliance and transparency obligations.
Precedent value
The case may become a template for states that want to regulate platform process without directly commanding moderation decisions. The split opinion also gives challengers language for arguing that even process rules can compel speech when they force platforms to use a state-defined category.
Next milestone
The case returns to the 2nd Circuit, which must decide the federal First Amendment challenge. A decision date was not publicly reported.
Pharma antitrust: Pfizer exits one generic price-fixing case
Parties
Most U.S. states, the District of Columbia and four U.S. territories sued 36 defendants in a sweeping generic-drug price-fixing case. Pfizer and its former Greenstone unit were among the defendants addressed in this week's ruling. 5
Claims
The states accused the defendants of conspiring to fix prices for 80 generic drugs. As to Pfizer and Greenstone, the states alleged bid-rigging and customer-allocation conduct involving six products, including generic Eplerenone tablets, Latanoprost drops and versions of Clindamycin phosphate. 5
Current stage
Chief Judge Michael Shea of the federal district court in Connecticut dismissed Pfizer from the case. He found that no reasonable jury could conclude Pfizer directly conspired, knew of Greenstone collusion when approving price changes, or was liable because Greenstone acted as its agent. 5
Recent developments
The states pointed to more than 360 calls and texts between Greenstone executives and Sandoz, but the court rejected the parent-liability theory against Pfizer. Connecticut Attorney General William Tong said his office is reviewing the decision and will continue pursuing claims against other defendants. Pfizer said it was pleased with the dismissal and that Greenstone was a reliable supplier of affordable generics. 5
Business impact
The ruling gives branded-drug parents and authorized-generic affiliates a defense roadmap: corporate ownership and strategic benefit are not enough by themselves to prove agency or knowing participation in a price-fixing conspiracy. State AGs will need tighter evidence linking parent-level approval to specific collusive conduct.
Precedent value
The decision matters beyond Pfizer because large pharma companies often use subsidiaries or authorized-generic units for lifecycle and market-access strategies. If the ruling holds, plaintiffs in generic-drug antitrust cases will face a higher evidentiary burden when they try to pull parent companies into subsidiary-level conduct.
Next milestone
No appeal deadline or schedule was reported. The states are reviewing the ruling, and claims against other defendants continue.
Pharma antitrust: FTC backs CareFirst in J&J Stelara appeal
Parties
CareFirst of Maryland and related CareFirst entities brought antitrust claims against Johnson & Johnson and Janssen Biotech over Stelara, the ustekinumab biologic used for psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease. The FTC entered the appeal as amicus curiae. 7
Claims
CareFirst alleges that J&J willfully maintained monopoly power in the market for Stelara through anticompetitive conduct, including the 2020 acquisition of Momenta Pharmaceuticals and later assertion of Momenta's patent portfolio against Amgen and other ustekinumab biosimilar makers. 7
Current stage
The case is on appeal in the Fourth Circuit after the Eastern District of Virginia reversed its earlier denial of summary judgment and required CareFirst to show that J&J specifically intended to exclude rivals. The FTC filed its amicus brief on June 23. 6
Recent developments
The FTC argues that Section 2 monopolization focuses on effects on competition and harm to consumers, not proof that the defendant specifically intended anticompetitive consequences. It said monopolization requires general intent to perform the act that results in or maintains monopoly power. 8
Business impact
A reversal would strengthen payor and biosimilar challenges to biologic life-cycle strategies. The FTC is not asking the Fourth Circuit to decide that CareFirst wins; it is asking the court to reject an intent requirement that would make Section 2 cases harder to bring in pharmaceutical markets.
Precedent value
The appeal could clarify whether a plaintiff challenging a biologic monopoly strategy must prove the defendant's specific exclusionary purpose, or whether evidence of conduct that maintains monopoly power is enough. That distinction matters for acquisitions and patent-assertion campaigns aimed at biosimilar entry.
Next milestone
No oral-argument date or briefing deadline was reported in the reviewed sources. The next milestone is the Fourth Circuit's handling of the summary-judgment standard.
Watch points for the next cycle
- The July 27 California state-court social-media addiction trial is the most concrete date on the tracker. A settlement by Meta, Snap or TikTok would signal that the first plaintiff verdict has changed trial-risk math; a trial would give the industry a second liability data point.
- The Richner/OpenAI/Microsoft case should be watched for early coordination with other AI copyright suits in the Southern District of New York. The local-news plaintiff group may push market-harm arguments that differ from author and reference-publisher cases.
- The J&J/Stelara appeal is the pharma antitrust item with the cleanest precedent question this week: whether Section 2 requires specific intent in this setting.
References
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.